menu search

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results
Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for EMPAVELI® (pegcetacoplan) SYFOVRE showed continued strong demand with growth week-over-week starting in August; permanent J-code effective as of October 1 Completed corporate restructuring aimed at driving growth of SYFOVRE and EMPAVELI and strengthening operational […] The post Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results a... Read More
Posted: Nov 1 2023, 11:05
Author Name: forextv
Views: 040986

Search within

Pages Search Results: